All CD44 CD44 antigen antibodies

CD44 is a cell-surface glycoprotein that plays a role in cell–cell interactions, cell adhesion and migration. It is encoded by the CD44 gene on chromosome 11 in humans. CD44 has been referred to as HCAM (homing cell adhesion molecule), Pgp-1 (phagocytic glycoprotein-1), Hermes antigen, lymphocyte homing receptor, and HUTCH-I.
CD44 has been shown to be involved in many physiological processes such as lymphocyte homing and activation, hematopoiesis, wound healing, and tumor metastasis. It is also involved in the regulation of the immune system. CD44 is expressed on a wide variety of cells including leukocytes, endothelial cells, fibroblasts, and epithelial cells.
CD44 has been identified as a potential target for cancer therapy due to its overexpression in many types of cancer cells. The use of CD44-targeted therapies has shown promising results in preclinical studies. In addition to cancer therapy, CD44-targeted therapies have also been investigated for the treatment of inflammatory diseases such as rheumatoid arthritis.
In summary, CD44 is a cell-surface glycoprotein that plays a role in cell–cell interactions, cell adhesion and migration. It is involved in many physiological processes such as lymphocyte homing and activation, hematopoiesis, wound healing, and tumor metastasis. CD44 has been identified as a potential target for cancer therapy due to its overexpression in many types of cancer cells. CD44-targeted therapies have also been investigated for the treatment of inflammatory diseases such as rheumatoid arthritis.